Table 2.

Pharmacokinetics of resveratrol and three metabolites in the plasma of volunteers after a single oral dose

VariableDose level (g)
0.51.02.55.0
Resveratrol
    AUCinf (ng h/mL)223.7*544.8 (57.2)786.5 (36.2)1,319 (59.1)
    Cmax (ng/mL)72.6 (48.9)117.0 (73.1)268.0 (55.3)538.8 (72.5)
    Tmax (h)0.833 (0.5-1.5)0.759 (0.5-4.0)1.375 (0.5-4.0)1.500 (0.67-5.0)
    Cav (ng/mL)8.36 (57.8)18.04 (51.6)32.25 (43.0)51.90 (80.7)
    Half-life (h)2.85*8.87 (91.1)4.22 (51.6)8.52 (95.8)
    CL/F (L/h)2,235*2,593 (65.1)3,471 (29.9)4,930 (50.0)
    CLR (L/h)1.177 (102.5)0.696 (71.5)0.656 (53.1)1.443 (139.2)
    V/F (liters)9,198*19,298 (54.3)22,226 (67.3)66,991 (112)
Glucuronide 1
    AUCinf (ng h/mL)1,919 (33.6)3,059 (60.9)5,664 (27.7)9,923 (40.9)
    Cmax (ng/mL)404.6 (35.3)473.6 (76.8)874.4 (37.5)1,285 (55.4)
    Tmax (h)2.00 (1.0-6.0)2.250 (1.0-6.0)2.375 (1.0-8.0)2.00 (1.5-5.0)
    Cav (ng/mL)76.9 (37.2)110.3 (56.1)215.5 (43.5)344.1 (51.5)
    Half-life (h)2.85 (48.6)7.27 (93.9)10.6 (92.9)7.90 (39.1)
    CL/F (L/h)282.7 (27.3)493.5 (74.7)469.5 (25.7)590.6 (45.2)
Glucuronide 2
    AUCinf (ng h/mL)1,287 (21.7)2,589 (66.4)4,320 (32.9)8,546 (62.3)
    Cmax (ng/mL)369.5 (39.6)672.6 (81.1)1,626 (71.5)1,735 (66.4)
    Tmax (h)1.500 (1.0-5.0)1.750 (1.0-5.1)2.000 (1.0-6.0)2.520 (1.5-8.0)
    Cav (ng/mL)51.0 (27.6)99.9 (66.2)193.8 (39.3)317.8 (65.6)
    Half-life (h)3.09 (69.8)6.64 (92.1)8.42 (88.9)5.83 (51.2)
    CL/F (L/h)408.8 (26.7)642.5 (83.0)636.9 (32.6)1,017 (94.6)
3-Sulfate
    AUCinf (ng h/mL)4,049 (26.6)10,053 (73.2)16,984 (41.7)30,898 (46.1)
    Cmax (ng/mL)1,135 (25.7)2,102 (81.3)2,786 (27.2)4,294 (48.0)
    Tmax (h)1.500 (1.0-5.0)2.000 (1.0-5.0)2.000 (1.0-5.2)2.050 (1.0-6.0)
    Cav (ng/mL)172.0 (23.2)402.6 (70.5)597.0 (27.0)1,089 (49.4)
    Half-life (h)3.21 (56.6)4.51 (82.8)11.5 (95.5)7.71 (42.3)
    CL/F (L/h)131.2 (25.8)151.8 (62.7)171.2 (40.0)207.8 (63.9)
  • NOTE: Values are the mean of n = 10 with coefficient of variation (in percent) or range in brackets.

    Abbreviations: AUCinf, area under the concentration versus time curve to time infinity; Cmax, maximal plasma concentration; Tmax, median time of maximal plasma concentration; Cav, average plasma concentration; CL/F, apparent total body clearance (calculated as dose/AUCinf); CLR, apparent renal clearance approximated by amount excreted with urine within 24 h over AUC0-24; V/F, apparent volume of distribution.

  • * n = 1, value for AUCinf at the lowest dose could be established in only one participant.